Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

evinacumab

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

- PMLiVE

Regeneron top science employer, says survey

Ranked highest for third year in a row

- PMLiVE

Amgen files lawsuit to block PCSK9 rivals

Firm suing Sanofi and Regeneron for patent infringement

Sanofi reception

Trial suggests Sanofi’s asthma drug works in sinusitis

Dupilumab able to reduce polyp size in sinusitis patients

- PMLiVE

Sanofi/Regeneron’s alirocumab ‘cuts cardiovascular events’

Data presented at ESC Congress demonstrates lower rates of cardiac death, stroke and more

Sanofi reception

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Buy FDA priority review voucher from BioMarin

- PMLiVE

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Regulator to assess neurocognitive effects of cholesterol drug

Bayer symbol

Bayer and Regeneron to develop second wet AMD therapy

Will collaborate on drug to be used in combination with Eylea

Sanofi reception

Sanofi and Regeneron’s cholesterol antibody aces phase III trial

Results confirm companies' lead over Amgen, Pfzer, Roche and Novartis

- PMLiVE

Bayer’s Eylea data not suitable, says IQWiG

German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links